Skip to content
Study details
Enrolling now

Propranolol Trial for Aggression and Self-Injury in People with Autism

Jeremy Veenstra-vanderweele
NCT IDNCT07091279ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 3.1 years

Ages

12–40

Locations

2 sites in NY

About this study

This trial is testing if propranolol can help reduce aggression, self-injury, and severe disruptive behaviors in people with autism. Participants will receive either propranolol or a placebo daily for 12 weeks. After the initial period, some participants may continue receiving propranolol for another 12 weeks.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take Propranolol
PhasePhase 2
DrugPropranolol
Primary goalIncidence of safety concerns and side effects associated with high-dose propranolol, including changes in blood pressure, pulse, and occurrence of dysrhythmias

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

propranolol (Non-selective beta blocker; slows heart rate)

Endpoints

Primary: Incidence of safety concerns and side effects associated with high-dose propranolol, including changes in blood pressure, pulse, and occurrence of dysrhythmias.

Body systems

Psychiatry / Mental Health